Bunge Ltd. (BG) Financials Nov 20, 2014, 4:33 p.m.
Income
Bunge Ltd. (BG) Financials Nov 20, 2014, 4:33 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Bunge Ltd.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 41.93B 45.71B 58.74B 60.99B 61.35B
Cost of Goods Sold (COGS) incl. D&A 40.37B 43.11B 56.05B 57.7B 59.22B
COGS excluding D&A 39.92B 42.66B 55.53B 57.13B 58.65B
Depreciation & Amortization Expense 443M 443M 526M 570M 568M
Depreciation 427M 420M 497M 504M 524M
Amortization of Intangibles 16M 23M 29M 66M 44M
Gross Income 1.56B 2.6B 2.69B 3.29B 2.13B
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 1.34B 1.56B 1.55B 1.53B 1.55B
Research & Development 26M 24M 22M 19M 19M
Other SG&A 1.32B 1.53B 1.53B 1.51B 1.53B
Other Operating Expense 0 0 22M 0 0
Unusual Expense 357M 180M (77M) 1.18B (380M)
EBIT after Unusual Expense (357M) (180M) 77M (1.18B) 380M
Non Operating Income/Expense 444M 2.42B (55M) 41M 359M
Non-Operating Interest Income 122M 69M 101M 53M 76M
Equity in Affiliates (Pretax) 0 - - 0 0
Interest Expense 283M 298M 302M 294M 383M
Gross Interest Expense 283M 298M 510M 553M 387M
Interest Capitalized 0 0 208M 259M 4M
Pretax Income 145M 3.05B 940M 372M 1.01B
Income Tax (110M) 689M 44M (6M) 904M
Income Tax - Current Domestic 58M 33M 7M 98M 33M
Income Tax - Current Foreign 39M 499M 236M 117M 411M
Income Tax - Deferred Domestic 13M 12M 29M (22M) 18M
Income Tax - Deferred Foreign (217M) 148M (246M) (199M) 442M
Income Tax Credits 3M 3M (18M) 0 0
Equity in Affiliates 80M 27M 44M 0 0
Other After Tax Income (Expense) - - - 0 0
Consolidated Net Income 335M 2.39B 940M 378M 110M
Minority Interest Expense (26M) 34M (2M) (28M) (57M)
Net Income 361M 2.35B 942M 406M 167M
Extraordinaries & Discontinued Operations 0 0 0 (342M) 97M
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 112M
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 (342M) (15M)
Net Income After Extraordinaries 361M 2.35B 942M 64M 264M
Preferred Dividends 78M 67M 34M 36M 34M
Net Income Available to Common 283M 2.29B 908M 370M 133M
EPS (Basic) 2.24 16.20 6.19 0.19 0.80
Basic Shares Outstanding 126.45M 141.19M 146.58M 146M 147.2M
EPS (Diluted) 2.22 14.63 5.85 0.19 0.80
Diluted Shares Outstanding 127.67M 156.27M 155.21M 147.14M 148.26M
EBITDA 662M 1.49B 1.65B 2.33B 1.15B
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Lilly's Breakthrough in Diabetes Treatment Eli Lilly's retatrutide is stirring up the diabetes treatment waters. The latest Phase 3 comparison to Ozempic's top dose reveals some surprising results. I'm not one to toss out kudos lightly, but this could be a genuine game-changer if things hold steady. A1C Reductions: A Close Look at the Numbers We’re staring down the...
Continue Reading
The Grand Unveiling: November Highlights Look at this: space nerds, dreamers, and just about anybody with a heartbeat and a sense of wonder should circle November 13, 2026, like a kid with a candy store gift card. That's when the California Science Center throws open the doors to the Samuel Oschin Air and Space Center. You might as well slap a 'world's first' sticker on...
Continue Reading
The Unicycive Landslide: What Went Down? Investors, buckle up. Unicycive Therapeutics Inc. (NASDAQ: UNCY) finds itself deep in the muck of a securities class action. Chief honchos, CEO Shalabh Gupta and CFO John Townsend, are taking the heat for allegedly controlling company disclosures that led shareholders to believe in non-existent progress with their third-party...
Continue Reading
Natural Gas Abundance Meets Conversion Hurdles It’s a wild scene when you've got oodles of natural gas but struggle to get it into AI data centers. That’s the picture today: U.S. gas production hitting a high of 137 billion cubic feet daily, while converting that gas into practical energy is the real challenge. You see, the gas market is ready to rumble, ticking...
Continue Reading
Shifting Gears at Ameritas: New VP Takes the Helm Well, chalk one up for Ameritas on this move. They've just brought on Ying Zhao as the new vice president of actuarial and financial strategy. It's a mouthful of a title, sure, but it's the role itself that's worth watching. Ameritas, for those not tracking, is a major player in the insurance and financial universe, doing...
Continue Reading
A New Era for Franchise Onboarding Just when you think the sports card world couldn't get any more niche, along comes Replay Sports Cards thumping its chest with some serious innovation. This Charlotte-based franchise just snagged the Franchise Innovation Award from Franchise Update Media. Yep, they're the only ones getting tips of the hat for the Most Innovative...
Continue Reading
Immersive Horror in Moreno Valley Walking straight into the fog of your nightmares isn't for the faint-hearted, but that's the kind of thrill the Moreno Valley Museum & ArtSpace is serving up with its new Dead by Daylight Immersive Experience. Kicking off just in time for Halloween on October 30, this isn't your average stroll in a museum—it's a heart-pounding,...
Continue Reading
Where Luxury Meets Thoughtfulness Residences by Armani/Casa Miami just nabbed a VERIFIED™ Luxury Residences badge from the Forbes Travel Guide folks. Now, you might be wondering why this is significant or if it's just another shiny tag in a world already glistening with luxury concepts. Well, there's a shift happening here, and it's got some meat to it. The folks...
Continue Reading
RedMane and South Dakota DSS: A New Milestone Talk about a leap into the digital age. South Dakota's Department of Social Services, teaming up with RedMane Technology, has just rolled out the Child Care Assistance Program on their BEES platform. That’s Benefits Eligibility and Enrollment System for those not keeping track. It represents a significant step in making life...
Continue Reading
Unmasking the Hype: QFIN's Pledge and Performance Investors, gather 'round because QFIN's latest uproar ain't pretty. The folks over at Qfin Holdings have found themselves in hot water, facing a class action lawsuit for allegedly pulling the wool over investors' eyes. Between March and August 2026, they promised a rock-solid ship braving China’s regulatory storm. Turns...
Continue Reading
Top 5 Most Recently Viewed Articles
BCMGlobal's New Role in Advancing NFSC BCMGlobal has been appointed to strategically manage the National Financing Support Services Company (NFSC), elevating it to a leading independent loan servicer. This initiative aims to promote excellence in the sector. Supporting Saudi Arabia's Financial Vision The NFSC, established with the backing of the Saudi Real Estate...
Continue Reading
Innovative Insights into MRD Testing Myriad Genetics, Inc. (NASDAQ: MYGN), a prominent name in molecular diagnostics and precision medicine, is set to unveil exciting new clinical findings related to their Precise MRD test at a significant annual meeting dedicated to cancer research. Presentation Highlights During the conference, Dr. Chad Tang from The University of Texas...
Continue Reading
SBM Offshore's Share Buyback Program Overview SBM Offshore has recently reported on its significant share repurchase program, valued at EUR130 million (approximately US$140 million), covering transactions made from November 21, 2024, to November 27, 2024. This initiative underscores the company’s commitment to enhancing shareholder value through systematic buybacks. Key...
Continue Reading
Akero Therapeutics Under Investigation by Berger Montague Berger Montague PC, a respected law firm, recently brought to attention an ongoing investigation into the practices of Akero Therapeutics, Inc. The investigation focuses on potential breaches of fiduciary duties and violations of federal securities laws by Akero’s Board of Directors, which has crucial...
Continue Reading
Nkarta to Engage with Investors in H.C. Wainwright Series Nkarta, Inc. (NASDAQ: NKTX), a pioneering clinical-stage biopharmaceutical firm dedicated to creating innovative engineered natural killer (NK) cell therapies, recently announced its notable role in the H.C. Wainwright "HCW@Home" Series. This virtual series will allow investors and interested parties to gain deeper...
Continue Reading